Skip to main content
. 2016 Feb 8;34(6):1140–1150. doi: 10.1097/HJH.0000000000000890

FIGURE 1.

FIGURE 1

Odds ratios for characteristics associated with blood pressure target of >130/80 mmHg at baseline in the LEADER trial. ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LCL, lower confidence interval; LDL, low-density lipoprotein; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results; UCL, upper confidence interval.